Lion Point Capital, LP Fennec Pharmaceuticals Inc. Transaction History
Lion Point Capital, LP
- $10.5 Million
- Q3 2025
A detailed history of Lion Point Capital, LP transactions in Fennec Pharmaceuticals Inc. stock. As of the latest transaction made, Lion Point Capital, LP holds 123,000 shares of FENC stock, worth $996,300. This represents 10.73% of its overall portfolio holdings.
Number of Shares
123,000
Previous 195,700
37.15%
Holding current value
$996,300
Previous $1.62 Million
30.36%
% of portfolio
10.73%
Previous 18.24%
Shares
5 transactions
Others Institutions Holding FENC
# of Institutions
86Shares Held
14.2MCall Options Held
10KPut Options Held
83.8K-
Southpoint Capital Advisors LP New York, NY4.08MShares$33 Million1.08% of portfolio
-
Sonic Gp LLC Honolulu, HI2.41MShares$19.5 Million33.54% of portfolio
-
Solas Capital Management, LLC Darien, CT2.19MShares$17.7 Million14.46% of portfolio
-
Black Rock Inc. New York, NY1.19MShares$9.62 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA956KShares$7.74 Million0.0% of portfolio
About FENNEC PHARMACEUTICALS INC.
- Ticker FENC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,067,300
- Market Cap $211M
- Description
- Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...